Major considerations and updates in immunotherapy for advanced prostate cancer
“People's concepts of immunotherapy are unfortunately quite distorted. It is not just about checkpoint inhibitors,” says Susan F. Slovin, MD, PhD.
In this video, Susan F. Slovin, MD, PhD, discusses takeaways of her presentation on immunotherapy in advanced prostate cancer, which was given at the 15th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies, and upcoming research. Slovin is a medical oncologist at the Memorial Sloan Kettering Cancer Center in New York City, New York.
Study: Lower PCSM is seen with radical prostatectomy vs other modalities
November 14th 2023"This large registry study with data from varied practice settings, incorporating the most commonly used treatment modalities, provides useful data on the long-term mortality outcomes," writes Badar M. Mian, MD.
Comparing Leuprolide Formulations in Advanced Prostate Cancer
November 13th 2023In the third article of the series, Melanie McGilloway, NP-C, an advanced practice provider at Genesis Urology in San Diego, discusses the various formulations of leuprolide, a gonadotropin-releasing hormone (GnRH) agonist used for treating advanced prostate cancer.
